Trial Profile
Phase IIb trial of FV 100 in patients with herpes zoster infections
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2019
Price :
$35
*
At a glance
- Drugs Valnivudine (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Hepion Pharmaceuticals
- 09 Dec 2014 Status changed from planning to not yet recruiting, according to a ContraVir Pharmaceuticals media release.
- 08 Jul 2014 ContraVir Pharmaceuticals now plans to initiate this phase IIb trial. ContraVir Pharmaceuticals spin off of Synergy Pharmaceuticals and became an independent public company in January 2014.
- 08 Jul 2014 Planned initiation date changed from 1 Jun 2012 to 1 Oct 2014 according to a ContraVir Pharmaceuticals media release.